FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Zealand Pharma NDA Filed for Diabetes Rescue Pen

Zealand Pharma submits an NDA for HypoPal (dasiglucagon) rescue pen for treating diabetes patients with severe hypoglycemia.

Medical Devices

Abbott Covid-19 Test Has High False Negatives: Study

New York University researchers say that a comparative study showed that Abbott Laboratories ID Now Covid-19 rapid test missed a third of the samples ...

Federal Register

Info Collection Extension on MedSun Reporting

Federal Register notice: FDA sends to OMB an information collection extension for Adverse Event Program for Medical Devices (Medical Product Safety Ne...

Federal Register

Info Collection on Certifications for Product Submissions

Federal Register notice: FDA seeks comments on an information collection extension entitled Certification to Accompany Drug, Biological Product, and D...

Medical Devices

Third-Party Review Guidance Explained

CDRH policy analyst Allen Hill explains the voluntary 510(k) third-party review program in a Webinar presentation.

Human Drugs

Individualized Therapeutics Workshop Transcript Out

CBER releases the transcript from a 3/3 public workshop on individualized therapeutics regulated by the Center.

Human Drugs

Refusal-to-File letter on BMS/Bluebird BLA

FDA issues a refusal to file letter to Bristol Myers Squibb and Bluebird Bio for a BLA for idecabtagene vicleucel, indicated for treating patients wit...

Human Drugs

MasterPharm Recalls Finasteride Due to High Drug Levels

MasterPharm recalls one lot of finasteride plus 1.25mg capsules because they were found to contain higher levels of minoxidil, an antihypertensive dru...

Human Drugs

Lack of Evidence for Compounded Pain Creams: Report

A National Academies report finds no evidence to support the safety or effectiveness of compounded topical pain creams.

Human Drugs

Compounded Drug MOU Out for Viewing

FDA releases for public viewing a memorandum of understanding between the agency and states on regulation of drug compounding.